APIM Therapeutics
Manufacturing · Norway · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Rådhusveien 12, Rissa, Sor-Trondelag, 71...Phone Number
+47 73494002Website
www.apimtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About APIM Therapeutics
APIM Therapeutics AS is a biotech company that originated as a venture-capital financed spin-off from the Norwegian University of Science and Technology. The company focuses on developing innovative peptide drugs, particularly its lead candidate ATX-101, which targets stress responses in cancer cells and has been tested in patients with ovarian cancer and sarcoma. Their goal is to create novel cancer treatments that address significant unmet patient needs by exploiting a unique therapeutic intervention point. APIM Therapeutics aims to advance its drug pipeline to provide effective solutions for cancer therapy.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is APIM Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if APIM Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if APIM Therapeutics had a recent Job posting/layoffs
APIM Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at APIM Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if APIM Therapeutics is spiking on competitors!
Product Launch: Get notified when APIM Therapeutics launches new products
Funding: Get notified immidiatlly once APIM Therapeutics has new funding data
Earning: See what the market has to say on APIM Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
APIM Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
APIM Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about APIM Therapeutics.
APIM Therapeutics Tech Stack
A closer look at the technologies used by APIM Therapeutics
See more technologies
APIM Therapeutics News & Media
APIM THERAPEUTICS ANNOUNCEs PUBLICATION OF PRECLINICAL RESEARCH OF ATX-101 IN GLIOBLASTOMA
APIM Therapeutics (APIM), a clinical stage biotech company, focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today the publication of research data of ATX-101 in glioblastoma preclinical models in the peer reviewed journal Cancers. The article entitled “ATX-101, a Peptide Targeting PCNA, has antitumor efficacy alone or in combination with Radiotherapy in murine models of human glioblastoma” investigated ATX-101, the lead comAPIM THERAPEUTICS ANNOUNCES INITIATION OF PATIENT RECRUITMENT IN A SARCOMA PHASE II STUDY
Trondheim/New York, December 10, 2021 APIM Therapeutics (APIM), a clinical stage biotech company focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia University Irving Medical Center. The clinical study (ClinicalTrials.gov Identifier: NCT05116683) will investigate ATX-101, the lead compound of APIM’s developAPIM THERAPEUTICS ANNOUNCES THAT THE FIRST PATIENT HAS BEEN TREATED WITH ATX-101 IN A PHASE I/II OVARIAN CANCER STUDY
Trondheim, 25 November 2021 APIM Therapeutics (APIM), a clinical stage biotech company, focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), announced today that the first patient has been treated in a clinical Phase 1b/2a study in ovarian cancer. The clinical study (ClinicalTrials.gov Identifier: NCT04814875) investigates ATX-101, the lead compound of APIM’s development program, in combination with platinum-based chemotherapy in patientsAPIM THERAPEUTICS COMPLETES PRIVATE PLACEMENT AND ENTERS PHASE-2 CLINICAL DEVELOPMENT
Trondheim, 18 May 2021 APIM Therapeutics AS (“APIM Therapeutics” or the “Company”), an oncology focused biotechnology company developing innovative anti-cancer treatments targeting stress responses in tumor cells, is pleased to announce the completion of a private placement directed towards existing and certain new investors in the Company (the “Private Placement”). “We are pleased to welcome 11 new investors to our existing strong shareholder base. The proceeds from this round put APIM Therapeu
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding APIM Therapeutics
Sign Up For FreeTo access detailed company insights
APIM Therapeutics AS is a biotech company that originated as a venture-capital financed spin-off from the Norwegian University of Science and Technology. The company focuses on developing innovative peptide drugs, particularly its lead candidate ATX-101, which targets stress responses in cancer cells and has been tested in patients with ovarian can... Read More
